Literature DB >> 8811506

The systemic administration of tacrine or selegiline facilitate spatial learning in aged fisher 344 rats.

L Yavich1, J Sirviö, A Haapalinna, T Puumala, E Koivisto, E Heinonen, P J Riekkinen.   

Abstract

When compared to young Fisher 344 rats, aged Fisher 344 rats were impaired in their acquisition of the water maze task as indicated by longer escape latencies and distances to find a hidden platform. In a free swim trial which was performed after the training period, young rats had a better spatial bias, since they spent more time swimming in the previous training quadrant. Tacrine 3 mg/kg, an anticholinesterase, and selegiline 0.25 mg/kg, a MAO-B inhibitor, partially reversed the acquisition deficit in aged rats when administered on their own, and drug-treated aged rats swam more in the previous training quadrant than vehicle-treated aged rats during the free swim trial. Aged rats also swam slower than young rats. Tacrine, but not selegiline, increased swimming speed in aged rats. Taken as a whole, these data support the proposal that tacrine may be effective at alleviating age-related learning impairment and confirm the role of cholinergic dysfunction in the spatial learning deficit in aged rats.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811506     DOI: 10.1007/BF01273158

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  20 in total

1.  Markers for biogenic amines in the aged rat brain: relationship to decline in spatial learning ability.

Authors:  M Gallagher; R D Burwell; M H Kodsi; M McKinney; S Southerland; L Vella-Rountree; M H Lewis
Journal:  Neurobiol Aging       Date:  1990 Sep-Oct       Impact factor: 4.673

Review 2.  R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.

Authors:  J Knoll
Journal:  J Neural Transm Suppl       Date:  1987

3.  The effect of subchronic administration of vigabatrin on learning and memory in nonepileptic rats.

Authors:  J Sirviö; A Ylinen; H Lahtinen; A Ronkainen; P Riekkinen; T Halonen; P J Riekkinen
Journal:  Pharmacol Biochem Behav       Date:  1991-05       Impact factor: 3.533

Review 4.  The molecular pharmacology of L-deprenyl.

Authors:  M Gerlach; P Riederer; M B Youdim
Journal:  Eur J Pharmacol       Date:  1992-06-05       Impact factor: 4.432

5.  Loss of muscarinic M1 receptors with aging in the cerebral cortex of Fisher 344 rats.

Authors:  R D Schwarz; A A Bernabei; C J Spencer; T A Pugsley
Journal:  Pharmacol Biochem Behav       Date:  1990-03       Impact factor: 3.533

6.  Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.

Authors:  G Engberg; T Elebring; H Nissbrandt
Journal:  J Pharmacol Exp Ther       Date:  1991-11       Impact factor: 4.030

7.  Endogenous dopamine facilitates striatal in vivo acetylcholine release by acting on D1 receptors localized in the striatum.

Authors:  S Consolo; P Girotti; G Russi; G Di Chiara
Journal:  J Neurochem       Date:  1992-10       Impact factor: 5.372

8.  Deprenyl alters behavior and caudate dopamine through an amphetamine-like action.

Authors:  C Okuda; D S Segal; R Kuczenski
Journal:  Pharmacol Biochem Behav       Date:  1992-12       Impact factor: 3.533

9.  Age-related changes on monoamine turnover in hippocampus of rats.

Authors:  J L Venero; C de la Roza; A Machado; J Cano
Journal:  Brain Res       Date:  1993-12-17       Impact factor: 3.252

10.  The interaction of L-deprenyl and scopolamine on spatial learning/memory in rats.

Authors:  L Yavich; J Sirviö; E Heinonen; P Riekkinen
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1993
View more
  1 in total

Review 1.  Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B.

Authors:  D P Holschneider; K Chen; I Seif; J C Shih
Journal:  Brain Res Bull       Date:  2001-11-15       Impact factor: 4.077

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.